Navigation Links
eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials
Date:6/19/2008

chTechnology (http://www.eRT.com) delivers technology-based products and services that enable pharmaceutical, biotechnological and medical device companies to collect, interpret and distribute cardiac safety and clinical data more efficiently. eRT is a market leader in centralized electrocardiographic (ECG) services-a core diagnostic capability-and a leading provider of technology and services that allow customers to automate and streamline data-based components of clinical trials, helping them bring new drugs to market faster.

Forward-looking statements

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including but not limited to 2008 financial guidance, involve a number of risks and uncertainties such as the company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
2. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
3. Oridion Announces Major Medical Research and Congress Presentations
4. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
5. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
6. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
7. Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device
8. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
9. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. XTENT Announces European Regulatory Update
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 1Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 2Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 3Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 4ClariVein 28TM 29 Catheter for Varicose Veins 3A Further Clinical Trial Results to Be Presented 5019 1ClariVein 28TM 29 Catheter for Varicose Veins 3A Further Clinical Trial Results to Be Presented 5019 2NewCardio Completes 242 9 Million Private Placement 57625 1NewCardio Completes 242 9 Million Private Placement 57625 2NewCardio Completes 242 9 Million Private Placement 57625 3NewCardio Completes 242 9 Million Private Placement 57625 4